

Farrukh T Awan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8049479/publications.pdf>

Version: 2024-02-01

208
papers

6,230
citations

94433

37
h-index

74163

75
g-index

213
all docs

213
docs citations

213
times ranked

7004
citing authors

#	ARTICLE	IF	CITATIONS
1	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	27.0	785
2	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	7.1	498
3	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016, 374, 2530-2541.	27.0	383
4	<i>BTK</i> ^{C481S} -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1437-1443.	1.6	367
5	Ibrutinib treatment improves T cell number and function in CLL patients. <i>Journal of Clinical Investigation</i> , 2017, 127, 3052-3064.	8.2	280
6	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e114-e126.	4.6	181
7	Hypertension and incident cardiovascular events following ibrutinib initiation. <i>Blood</i> , 2019, 134, 1919-1928.	1.4	155
8	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <i>Blood Advances</i> , 2019, 3, 1553-1562.	5.2	145
9	Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 2519-2525.	1.6	144
10	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
11	Wnt'er in liver: Expression of Wnt and frizzled genes in mouse. <i>Hepatology</i> , 2007, 45, 195-204.	7.3	131
12	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	1.4	130
13	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748.	5.2	123
14	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. <i>Cancer Discovery</i> , 2018, 8, 1300-1315.	9.4	115
15	CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain ⁺ engineered monoclonal antibody. <i>Blood</i> , 2010, 115, 1204-1213.	1.4	112
16	Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. <i>Oncolmmunology</i> , 2016, 5, e1226720.	4.6	105
17	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
18	Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2012, 7, 567-578.	2.7	85

#	ARTICLE	IF	CITATIONS
19	Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. <i>Journal of the American College of Cardiology</i> , 2018, 72, 697-698.	2.8	80
20	How we approach patient evaluation for hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 1259-1268.	2.4	71
21	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	1.6	71
22	Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. <i>Leukemia</i> , 2019, 33, 2527-2530.	7.2	65
23	A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 1302-1308.	1.4	62
24	Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. <i>Blood</i> , 2009, 113, 535-537.	1.4	61
25	Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1128-1135.	2.0	59
26	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. <i>Blood</i> , 2014, 124, 3553-3560.	1.4	56
27	A single-institution retrospective cohort study of first-line R ² -EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. <i>British Journal of Haematology</i> , 2018, 180, 259-266.	2.5	53
28	Phase I Trial of the Pan-PI3K Inhibitor Pivalarisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 3160-3169.	7.0	51
29	A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. <i>Haematologica</i> , 2018, 103, 1351-1358.	3.5	49
30	Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies. <i>Journal of the American College of Cardiology</i> , 2020, 75, 620-628.	2.8	49
31	New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms. <i>Clinical Cancer Research</i> , 2014, 20, 5869-5874.	7.0	45
32	PKC- β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. <i>Blood</i> , 2014, 124, 1481-1491.	1.4	45
33	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
34	Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. <i>Bone Marrow Transplantation</i> , 2013, 48, 1279-1284.	2.4	43
35	Role of thiamine in managing ifosfamide-induced encephalopathy. <i>Journal of Oncology Pharmacy Practice</i> , 2006, 12, 237-239.	0.9	42
36	The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. <i>Blood</i> , 2008, 111, 3901-3902.	1.4	42

#	ARTICLE	IF	CITATIONS
37	Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. <i>Blood Advances</i> , 2019, 3, 447-460.	5.2	42
38	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021, 137, 216-231.	1.4	40
39	A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL). <i>Blood</i> , 2012, 120, 4317-4317.	1.4	40
40	Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma Effect. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 480-483.	2.0	38
41	Randomized phase 2 study of otlertuzumab and bendamustine <i>versus</i> bendamustine in patients with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 618-628.	2.5	36
42	Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 556-567.	2.0	34
43	Otlertuzumab (TRU 016), an anti-CD 37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients. <i>British Journal of Haematology</i> , 2015, 168, 38-45.	2.5	33
44	Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1584-1588.	5.2	33
45	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	4.9	33
46	A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. <i>Annals of Hematology</i> , 2016, 95, 1137-1143.	1.8	31
47	Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials. <i>Circulation</i> , 2019, 139, 2594-2596.	1.6	31
48	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab <i>versus</i> fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 466-477.	2.5	30
49	Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming. <i>Oncotarget</i> , 2016, 7, 40558-40570.	1.8	30
50	Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1972-1977.	1.3	29
51	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. <i>Blood</i> , 2017, 130, 830-830.	1.4	27
52	Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 27-38.	1.3	26
53	Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. <i>Journal of Clinical Apheresis</i> , 2013, 28, 359-367.	1.3	25
54	Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study. <i>Blood</i> , 2016, 128, 638-638.	1.4	23

#	ARTICLE	IF	CITATIONS
55	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	23
56	Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?. <i>Journal of Oncology Pharmacy Practice</i> , 2007, 13, 69-75.	0.9	22
57	Use of <sc>PD</sc>â€1 (<sc>PDCD</sc>1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. <i>British Journal of Haematology</i> , 2019, 185, 363-366.	2.5	22
58	Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 639-639.	1.4	22
59	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , 2015, 125, 284-295.	1.4	19
60	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , 2012, 120, 799-799.	1.4	19
61	RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 14632-14645.	1.8	19
62	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 320-329.	3.8	16
63	Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 343-355.e6.	0.4	15
64	Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 693-693.	1.4	15
65	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , 2014, 124, 636-636.	1.4	15
66	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. <i>Blood</i> , 2021, 138, 392-392.	1.4	15
67	Paraneoplastic Sweetâ€™s syndrome and the pathergy phenomenon. <i>Annals of Hematology</i> , 2007, 86, 613-614.	1.8	14
68	Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest. <i>Resuscitation</i> , 2019, 142, 30-37.	3.0	14
69	Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. <i>Blood Advances</i> , 2020, 4, 4860-4863.	5.2	14
70	Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2834-2840.	1.3	13
71	Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 1-12.e7.	0.4	13
72	Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e865-e875.	0.4	13

#	ARTICLE	IF	CITATIONS
73	Phase Ib trial of the <scp>PI</scp>3K</scp>mTOR</scp> inhibitor voxtalisib (<scp>SAR</scp>245409) in combination with chemoimmunotherapy in patients with relapsed or refractory Bâ€cell malignancies. British Journal of Haematology, 2016, 175, 55-65.	2.5	12
74	Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia. Haematologica, 2021, 106, 1608-1615.	3.5	12
75	Contemporary utilization patterns and outcomes of thrombolytic administration for ischemic stroke among patients with cancer. International Journal of Stroke, 2021, 16, 150-162.	5.9	12
76	Cardio-Oncology: A Win-Win Situation. Circulation, 2020, 142, 2456-2458.	1.6	11
77	Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).. Journal of Clinical Oncology, 2014, 32, 8506-8506.	1.6	11
78	International consensus statement on the management of cardiovascular risk of Brutonâ€™s tyrosine kinase inhibitors in CLL. Blood Advances, 2022, 6, 5516-5525.	5.2	11
79	Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2008, 49, 1893-1898.	1.3	10
80	Romiplostim resistance in secondary failure of platelet recovery. Journal of Oncology Pharmacy Practice, 2013, 19, 369-372.	0.9	10
81	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. British Journal of Haematology, 2019, 187, 399-402.	2.5	10
82	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2951-2951.	1.4	10
83	Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. Hematological Oncology, 2010, 28, 3-12.	1.7	9
84	Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. Journal of Oncology, 2012, 2012, 1-5.	1.3	9
85	Use of acalabrutinib in patients with mantle cell lymphoma. Expert Review of Hematology, 2018, 11, 495-502.	2.2	9
86	Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia. Supportive Care in Cancer, 2020, 28, 1799-1807.	2.2	9
87	Etoposide-induced posterior reversible encephalopathy syndrome. Annals of Hematology, 2013, 92, 561-562.	1.8	8
88	Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. Blood Reviews, 2018, 32, 159-166.	5.7	8
89	Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkinâ€™s Lymphoma Patients. Blood, 2013, 122, 4170-4170.	1.4	8
90	Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy. Blood, 2016, 128, 4387-4387.	1.4	8

#	ARTICLE	IF	CITATIONS
91	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. <i>Blood</i> , 2016, 128, 55-55.	1.4	8
92	Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 54-66.	1.7	7
93	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1099-1105.	2.0	7
94	Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. <i>Expert Review of Hematology</i> , 2022, 15, 321-331.	2.2	7
95	Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	7
96	Second allo-SCT from a different donor can improve severe steroid-resistant gut GVHD. <i>Bone Marrow Transplantation</i> , 2010, 45, 1658-1660.	2.4	6
97	Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 425-432.	0.9	6
98	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , 2013, 122, 106-106.	1.4	6
99	GEOGRAPHIC TONGUE INDUCED BY VENETOCLAX IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2019, 12, 11.	0.1	6
100	Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 146-148.	2.4	5
101	Administration of anti-thymocyte globulin: a comparison of two protocols. <i>Bone Marrow Transplantation</i> , 2014, 49, 1535-1537.	2.4	5
102	Cure for CLL?. <i>Blood</i> , 2016, 127, 274-274.	1.4	5
103	The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement. <i>Leukemia Research</i> , 2021, 100, 106480.	0.8	5
104	A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2018, 132, 3136-3136.	1.4	5
105	Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 2860-2860.	1.4	5
106	DNA Hypomethylation within B-Cell Enhancers and Super Enhancers Reveal a Dependency on Immune and Metabolic Mechanisms in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 1049-1049.	1.4	5
107	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. <i>Blood</i> , 2016, 128, 3238-3238.	1.4	5
108	Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7010-7010.	1.6	5

#	ARTICLE	IF	CITATIONS
109	Malignant Thymoma With Immunodeficiency (Good Syndrome) Associated With Mucormycosis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 109.	1.3	4
110	Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model. <i>Annals of Behavioral Medicine</i> , 2019, 53, 839-848.	2.9	4
111	Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway. <i>Blood</i> , 2016, 128, 3225-3225.	1.4	4
112	A Combined Biomarker of Bright CD38 and MYC is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2022, 158, 338-344.	0.7	4
113	Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 487.e1-487.e7.	1.2	4
114	Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1631-1634.	1.8	3
115	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 1039-1046.	2.2	3
116	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6187-6195.	7.0	3
117	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 716-721.	1.3	3
118	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019, 134, 1591-1591.	1.4	3
119	Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. <i>Blood</i> , 2011, 118, 2683-2683.	1.4	3
120	Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib. <i>Blood</i> , 2014, 124, 1997-1997.	1.4	3
121	Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study. <i>Blood</i> , 2014, 124, 329-329.	1.4	3
122	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
123	Gastrointestinal chronic graft-versus-host disease: management options. <i>Journal of Oncology Pharmacy Practice</i> , 2007, 13, 49-51.	0.9	2
124	Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. <i>American Journal of Hematology</i> , 2007, 82, 1120-1121.	4.1	2
125	The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2016, 9, 1177-1187.	2.2	2
126	Phase 1b Study of TRU-016, an Anti-CD37 SMIP, Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1795-1795.	1.4	2

#	ARTICLE	IF	CITATIONS
127	Final Results of a Phase I Study of the Fc Engineered CD19 Antibody XmAb [®] 5574 (MOR0208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).. Blood, 2012, 120, 2894-2894.	1.4	2
128	Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR™ Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 4671-4671.	1.4	2
129	Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling. Blood, 2015, 126, 1744-1744.	1.4	2
130	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 2953-2953.	1.4	2
131	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. Blood, 2016, 128, 2040-2040.	1.4	2
132	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. Blood, 2016, 128, 4385-4385.	1.4	2
133	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. Blood, 2016, 128, 4386-4386.	1.4	2
134	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. Blood, 2016, 128, 4388-4388.	1.4	2
135	Depth of response and progression free survival in CLL patients on ibrutinib.. Journal of Clinical Oncology, 2018, 36, 7514-7514.	1.6	2
136	Phase 1 Study of TRU-016, An Anti-CD37 SMIP [®] , [†] Protein in Relapsed and/or Refractory NHL Patients. Blood, 2011, 118, 1636-1636.	1.4	2
137	Phase 1 Study of Tru-016, An Anti-CD37 SMIP [®] , [†] Protein in Naïve and Relapsed and/or Refractory CLL Patients. Blood, 2011, 118, 1792-1792.	1.4	2
138	Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb [®] 5574 (aka) Tj ETQq0 0 0 rgBT /Overlock 10 Lymphocytic Lymphoma (SLL). Blood, 2014, 124, 1993-1993.	1.4	2
139	Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting. Blood, 2019, 134, 2810-2810.	1.4	2
140	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematological Oncology, 2022, 40, 49-57.	1.7	2
141	COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies. Blood, 2021, 138, 4134-4134.	1.4	2
142	Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting. Neuro-Oncology Practice, 2022, 9, 183-192.	1.6	2
143	Optimizing the Efficacy of Plerixafor as a Salvage Option In Poor Mobilizers Following Chemotherapy Plus G-CSF Mobilization. Biology of Blood and Marrow Transplantation, 2011, 17, S208-S209.	2.0	1
144	Ibrutinib: targeting the hidden CLL. Blood, 2014, 123, 3215-3216.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. , 2019, , 185-190.		1
146	Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e123-e128.	0.4	1
147	Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies. Blood, 2018, 132, 4423-4423.	1.4	1
148	Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 4185-4185.	1.4	1
149	Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy. Blood, 2019, 134, 3045-3045.	1.4	1
150	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. Blood, 2019, 134, 3039-3039.	1.4	1
151	CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy. Blood, 2020, 136, 22-23.	1.4	1
152	DNA Hypomethylation Leads to Aberrant Expression of PD-1 in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3504-3504.	1.4	1
153	Efficacy and Safety Of Treatments For Relapsed Or Refractory DLBCL: Results Of a Systematic Literature Review. Blood, 2013, 122, 5104-5104.	1.4	1
154	Targeting the Tumor Evasion Interaction of NKG2A and Its Ligand HLA-E Increases Natural-Killer Cell Activity in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1289-1289.	1.4	1
155	Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2016, 128, 4372-4372.	1.4	1
156	Congestive heart failure (CHF) in acute myeloid leukemia patients during induction.. Journal of Clinical Oncology, 2013, 31, 7105-7105.	1.6	1
157	A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US. Blood, 2013, 122, 5597-5597.	1.4	1
158	Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRâ„¢ Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 4165-4165.	1.4	1
159	Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2018, 36, 7528-7528.	1.6	1
160	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. Blood, 2018, 132, 4414-4414.	1.4	1
161	Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2019, 134, 4082-4082.	1.4	1
162	T-Cell Telomere Length As a Biomarker to Predict Outcome in Patients Receiving CAR-T Immunotherapy. Blood, 2021, 138, 4798-4798.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Single-Agent Rituximab and Ultra-Low-Dose Adaptive Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 4510-4510.	1.4	1
164	Clinical and Molecular Characteristics Associated with Vitamin C Deficiency in Myeloid Malignancies; Real World Data from a Prospective Cohort. <i>Blood</i> , 2021, 138, 1217-1217.	1.4	1
165	A Radiomic Machine Learning Model to Predict Treatment Response to Methotrexate and Survival Outcomes in Primary Central Nervous System Lymphoma (PCNSL). <i>Blood</i> , 2020, 136, 29-30.	1.4	1
166	A Multicenter Analysis of Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor for PB Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S182-S183.	2.0	0
167	Intravenous Busulfan Pharmacokinetics in Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Dosing Weight. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S373-S374.	2.0	0
168	Administration of Rabbit Anti-Thymocyte Globulin: Slowing Infusion Rate over a 4 Day Course with Aggressive Use of Pre-Medications May Decrease ATG Related Infusion Reactions. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S287-S288.	2.0	0
169	Choosing ibrutinib wisely. <i>Blood</i> , 2018, 131, 156-157.	1.4	0
170	Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.. <i>Blood</i> , 2007, 110, 4727-4727.	1.4	0
171	High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Incorporating Fludarabine, Busulfan, and Rabbit ATG.. <i>Blood</i> , 2007, 110, 5080-5080.	1.4	0
172	Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: Evidence of Graft-Versus-Lymphoma Effect.. <i>Blood</i> , 2007, 110, 3044-3044.	1.4	0
173	Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab.. <i>Blood</i> , 2008, 112, 2105-2105.	1.4	0
174	CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.. <i>Blood</i> , 2009, 114, 3725-3725.	1.4	0
175	Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation â€” A Multicenter Analysis. <i>Blood</i> , 2010, 116, 1351-1351.	1.4	0
176	Utility of Plerixafor In Addition to Chemotherapy and G-CSF Mobilization Regimens. <i>Blood</i> , 2010, 116, 4443-4443.	1.4	0
177	Allogeneic Transplantation Following Reduced Intensity Conditioning with Fludarabine and Melphalan In Patients with Advanced Myelofibrosis Is Associated with Unacceptable Rates of Acute Graft-Vs-Host Disease and Non-Relapse Mortality.. <i>Blood</i> , 2010, 116, 4552-4552.	1.4	0
178	Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting. <i>Blood</i> , 2011, 118, 4468-4468.	1.4	0
179	Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies â€” A Multicenter Analysis. <i>Blood</i> , 2011, 118, 313-313.	1.4	0
180	Genome-Wide DNA Methylation Landscape Defines IGHV Mutated and Unmutated B Cell Chronic Lymphocytic Leukemias. <i>Blood</i> , 2012, 120, 526-526.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies â€“ A Multicenter Analysis. <i>Blood</i> , 2012, 120, 4409-4409.	1.4	0
182	Decreasing early mortality (30-day) in APL patients with use of streamlined treatment guidelines and support from core group of experts.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7091-7091.	1.6	0
183	Congestive Heart Failure (CHF) During Induction In ACUTE Promyelocytic Leukemia (APL) Patients. <i>Blood</i> , 2013, 122, 3898-3898.	1.4	0
184	Serum Alkaline Phosphatase Level On Day 4 Of G-CSF Administration Could Be a Simple Yet Practical Surrogate Marker For CD34 Mobilization and Collection. <i>Blood</i> , 2013, 122, 4519-4519.	1.4	0
185	Efficacy and Safety Of Treatments For Relapsed Or Refractory Mantle Cell Lymphoma (MCL): Results Of a Systematic Literature Review. <i>Blood</i> , 2013, 122, 5099-5099.	1.4	0
186	Obinutuzumab may chart the way to improved QOL for CLL patients. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 113-114.	0.1	0
187	Abstract 5182: Identifying differential gene expression and splicing events in chronic lymphocytic leukemia patients through whole transcriptome profiling. , 2014, , .		0
188	Abstract 5180: Profiling signaling pathways in chronic lymphocytic leukemia using reverse phase protein array. , 2014, , .		0
189	Genome-Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2014, 124, 3552-3552.	1.4	0
190	Abstract 2191: Transcriptome analysis demonstrates the ability of the bromodomain inhibitor JQ1 to attenuate expression of common oncogenes heterogeneously expressed among chronic lymphocytic leukemia subsets. , 2015, , .		0
191	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vi tro Potency in B-Cell Malignancies. <i>Blood</i> , 2015, 126, 318-318.	1.4	0
192	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. <i>Blood</i> , 2016, 128, 3198-3198.	1.4	0
193	Analysis of an Online Decision Support Tool for Chronic Lymphocytic Leukemia: Disparities in Treatment Selection Between Experts and Community Practitioners. <i>Blood</i> , 2016, 128, 5958-5958.	1.4	0
194	BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma. <i>Blood</i> , 2016, 128, 2767-2767.	1.4	0
195	Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma. <i>Blood</i> , 2018, 132, 5322-5322.	1.4	0
196	Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment. <i>Blood</i> , 2018, 132, 3148-3148.	1.4	0
197	Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4724-4724.	1.4	0
198	Curriculum in Chronic Lymphocytic Leukemia Narrows the Educational Gaps of the Oncology Healthcare Team. <i>Blood</i> , 2019, 134, 5878-5878.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL. <i>Blood</i> , 2019, 134, 1759-1759.	1.4	0
200	The Association of Leukocyte Immunoglobulin-like Receptor B4 (LILRB-4) with Central Nervous System Involvement in Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S111.	2.0	0
201	Identification of Barriers of CAR-T Utilization in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1972-1972.	1.4	0
202	Ascorbate Deficiency Is Associated with Severity of Cytokine Release Syndrome Following Therapy with Chimeric Antigen Receptor T-Cells. <i>Blood</i> , 2021, 138, 4801-4801.	1.4	0
203	Evaluating the Impact of Therapy Related Healthcare Team Burden on Selection of Novel Therapies for Chronic Lymphocytic Leukemia and Lymphoid Malignancies. <i>Blood</i> , 2021, 138, 4015-4015.	1.4	0
204	Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
205	Evolving Treatment Patterns in Chronic Lymphocytic Leukemia Among Experts and Community Practitioners: Analysis of an Online Decision Support Tool. <i>Blood</i> , 2020, 136, 41-42.	1.4	0
206	Comparison of Demographics, Treatment Patterns and Outcomes Among Primary Central Nervous System Lymphoma (PCNSL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution within the Same Healthcare System. <i>Blood</i> , 2020, 136, 11-12.	1.4	0
207	Highlights in chronic lymphocytic leukemia from the 61st American Society of Hematology Annual Meeting and Exposition: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 3, 14-17.	0.3	0
208	Treatment Patterns, Outcomes and the Impact of Cellular Therapies in Secondary Central Nervous System Lymphoma (SCNSL): The UT Southwestern Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S417-S418.	1.2	0